- Perspective Therapeutics (CATX, Financial) to present key clinical data at ASCO 2025 Annual Meeting.
- Focus on two radiopharmaceutical programs: [212Pb]VMT-?-NET for neuroendocrine tumors (NETs) and [212Pb]VMT01 for melanoma.
- Presentations highlight significant dose-limiting toxicity follow-up and interim safety/efficacy results.
Perspective Therapeutics, Inc. (CATX), a leader in radiopharmaceutical development for cancer treatments, has announced that data from its [212Pb]VMT-?-NET and [212Pb]VMT01 programs are set to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3, 2025. These presentations will offer insights into the potential of their therapies to improve treatments for neuroendocrine tumors (NETs) and melanoma.
Thorvardur Halfdanarson will deliver an oral presentation on [212Pb]VMT-?-NET, which will cover dose-limiting toxicity observations after a one-year follow-up, as well as preliminary expansion results. This presentation is scheduled for May 30, 2025, at 4:09 PM CDT during the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session.
Meanwhile, Zachary Morris will be presenting a poster on interim safety and efficacy data of the [212Pb]VMT01 program targeting MC1R-expression in melanoma. This session will occur on June 2, 2025, between 1:30 and 4:30 PM CDT.
The company's ongoing trials aim to deliver the alpha-emitting isotope 212Pb directly to cancer cell sites, combining advanced molecular targeting with therapeutic radiopharmaceuticals. Perspective Therapeutics continues to expand its capabilities, enhancing their ability to provide innovative cancer treatments through their proprietary 212Pb generator system.
Further details about these presentations and the abstracts will be available from ASCO on May 22, 2025, at 5:00 PM EDT. These developments highlight Perspective Therapeutics' commitment to leveraging advanced technologies to pioneer effective cancer therapies, potentially impacting the company’s future drug development and market outlook.
